Zim Laboratories Ltd

Zim Laboratories Ltd

₹ 104 0.53%
28 May - close price
About

Incorporated in 1989, Zim Laboratories
Ltd manufactures formulation drugs and
pre formulation ingredients in India and
markets and sells these within and out
side India[1]

Key Points

Business Overview:[1]
ZLL is a EU-GMP, WHOGMP, NSF/ANSI 455-2 certified research-driven pharmaceutical company that develops, manufactures and supplies generic products in the oral solid dosage forms, both as pre-formulation intermediates ad finished formulations for certain key therapeutic segments. It offers both pharmaceutical and nutraceutical products.‍ Company has an in-house R&D capabilities to offer a range of non-infringing drug
delivery solutions based on process technologies

  • Market Cap 509 Cr.
  • Current Price 104
  • High / Low 153 / 89.5
  • Stock P/E 30.4
  • Book Value 47.6
  • Dividend Yield 0.00 %
  • ROCE 10.0 %
  • ROE 7.87 %
  • Face Value 10.0

Pros

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 1.96% over past five years.
  • Promoter holding is low: 33.3%
  • Company has a low return on equity of 9.80% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
73.17 63.64 75.73 86.02 104.11 92.50 99.26 100.32 104.45 67.01 85.26 95.82 117.39
64.65 58.71 67.05 75.38 90.43 81.12 87.14 87.68 89.40 62.47 76.29 84.64 101.96
Operating Profit 8.52 4.93 8.68 10.64 13.68 11.38 12.12 12.64 15.05 4.54 8.97 11.18 15.43
OPM % 11.64% 7.75% 11.46% 12.37% 13.14% 12.30% 12.21% 12.60% 14.41% 6.78% 10.52% 11.67% 13.14%
0.85 1.25 0.89 0.72 1.65 1.87 1.44 2.42 0.70 0.63 1.42 1.11 1.53
Interest 2.93 2.55 2.58 1.75 1.43 1.33 1.36 1.62 1.27 1.73 1.22 1.70 2.28
Depreciation 3.89 3.36 4.07 3.53 3.88 3.95 4.04 3.56 4.58 3.66 3.72 3.58 3.87
Profit before tax 2.55 0.27 2.92 6.08 10.02 7.97 8.16 9.88 9.90 -0.22 5.45 7.01 10.81
Tax % 45.88% 29.63% 31.51% 27.96% 35.73% 29.23% 30.64% 33.60% 27.88% 36.36% 23.30% 31.10% 26.92%
1.38 0.19 2.00 4.39 6.44 5.64 5.66 6.57 7.14 -0.14 4.18 4.83 7.89
EPS in Rs 0.28 0.04 0.41 0.90 1.32 1.16 1.16 1.35 1.47 -0.03 0.86 0.99 1.62
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
266 268 235 272 332 274 304 329 397 365
278 238 203 238 289 255 267 292 345 325
Operating Profit -12 30 32 34 43 20 37 38 51 40
OPM % -4% 11% 14% 13% 13% 7% 12% 12% 13% 11%
2 -2 5 9 2 5 -3 5 6 5
Interest 10 14 10 9 11 13 11 8 6 7
Depreciation 7 9 9 10 11 13 15 15 16 15
Profit before tax -27 5 18 24 23 -1 9 19 36 23
Tax % 19% 5% -6% 24% 30% 216% 35% 33% 30% 27%
-22 5 19 18 16 2 6 13 25 17
EPS in Rs 3.31 0.36 1.15 2.67 5.13 3.44
Dividend Payout % 0% 16% 4% 4% 5% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 2%
3 Years: 6%
TTM: -8%
Compounded Profit Growth
10 Years: %
5 Years: 1%
3 Years: 23%
TTM: -33%
Stock Price CAGR
10 Years: %
5 Years: 22%
3 Years: 52%
1 Year: 6%
Return on Equity
10 Years: %
5 Years: 8%
3 Years: 10%
Last Year: 8%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 8 8 8 8 16 16 16 16 49 49
Reserves 86 91 110 128 135 136 141 154 145 183
93 96 81 81 77 90 82 53 62 109
78 61 60 80 96 81 81 112 79 102
Total Liabilities 265 256 259 297 325 323 320 335 335 442
87 92 89 94 101 111 103 103 107 177
CWIP 6 3 4 8 13 10 10 11 26 24
Investments 0 0 0 0 5 8 8 8 8 8
172 161 166 195 206 194 199 213 193 234
Total Assets 265 256 259 297 325 323 320 335 335 442

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
22 32 37 37 21 32 47 35 11
-12 -7 -26 -23 -19 -6 -14 -35 -72
-10 -25 -10 -15 -2 -26 -33 1 60
Net Cash Flow -0 -0 1 -1 0 0 -0 1 -1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 111 120 137 119 99 84 77 90 81 100
Inventory Days 104 88 108 134 126 144 125 171 99 173
Days Payable 144 109 137 172 165 168 150 186 109 133
Cash Conversion Cycle 71 99 108 81 61 60 52 75 71 140
Working Capital Days 108 111 127 103 85 107 113 96 95 128
ROCE % 13% 14% 13% 15% 5% 10% 12% 17%

Shareholding Pattern

Numbers in percentages

9 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26% 33.26%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.06% 0.00% 0.00% 0.01%
66.74% 66.74% 66.74% 66.74% 66.74% 66.75% 66.73% 66.74% 66.69% 66.75% 66.74% 66.74%
No. of Shareholders 4,8874,6103,6463,5613,5693,6436,0275,8798,98215,30517,34217,100

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls